These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 21034677)

  • 1. Development of anti-cancer drugs.
    Arrondeau J; Gan HK; Razak AR; Paoletti X; Le Tourneau C
    Discov Med; 2010 Oct; 10(53):355-62. PubMed ID: 21034677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening and evaluation of anticancer agents.
    Zee-Cheng RK; Cheng CC
    Methods Find Exp Clin Pharmacol; 1988 Feb; 10(2):67-101. PubMed ID: 3283480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial designs for multiple myeloma.
    Hoering A; Crowley J
    Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodological aspects of lung cancer clinical trials in the era of targeted agents.
    Di Maio M; Gallo C; De Maio E; Morabito A; Piccirillo MC; Gridelli C; Perrone F
    Lung Cancer; 2010 Feb; 67(2):127-35. PubMed ID: 19875193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to the development and marketing approval of drugs that prevent cancer.
    Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
    Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
    Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C
    J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Goal of Cancer Treatment.
    Balis FM
    Oncologist; 1998; 3(4):V. PubMed ID: 10388118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.